HLB Life Science Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 21,429.51 million compared to KRW 15,868.22 million a year ago. Net loss was KRW 9,780.28 million compared to net income of KRW 6,594.74 million a year ago. Basic loss per share from continuing operations was KRW 96 compared to basic earnings per share from continuing operations of KRW 65.6082 a year ago. Diluted loss per share from continuing operations was KRW 96 compared to diluted earnings per share from continuing operations of KRW 65.6082 a year ago. Basic loss per share was KRW 96 compared to basic earnings per share of KRW 69 a year ago.
For the six months, sales was KRW 869.6 million compared to KRW 200.39 million a year ago. Net income was KRW 3,878.98 million compared to net loss of KRW 3,772.76 million a year ago. Basic earnings per share from continuing operations was KRW 38 compared to basic loss per share from continuing operations of KRW 38.0337 a year ago. Diluted earnings per share from continuing operations was KRW 38 compared to diluted loss per share from continuing operations of KRW 38.0337 a year ago. Basic earnings per share was KRW 38 compared to basic loss per share of KRW 40 a year ago.